The new Biotest
Plasma Center will provide the opportunity for area residents to donate plasma and thereby contribute the much needed source material used in the production of plasma-derived medicines that can treat rare and life threatening medical conditions.
In conjunction with the launch, the Biotest
plasma donor centre is joining the Grifols network of over 250 plasma donor centres as well as partnering with the Russellville community to help meet Grifols daily mission of improving the health and wellbeing of people around the world.
is a global supplier of plasma proteins and biotherapeutic drugs primarily used in clinical immunology, hematology and intensive care medicine.
To address these challenges, Germany-based Biotest
is using a special Late Stage Customization service from Schreiner MediPharm, a global provider of specialty pharmaceutical labeling products.
In various countries, different systems of WET or WEA biotest
data were applied as an alternative to a chemical approach (and/or permit limits).
Specialising in innovative haematology and immunology products, the firm is a subsidiary of Biotest
AG, a German-based global researcher and provider of plasma protein therapies that employs approximately 2,000 people worldwide.
Zinc sulphate heptahydrate (ZnS[O.sub.4] x 7[H.sub.2]O) is a standard toxicant in biotest
for bacterial bioluminescence in the test system "Ekolum" (selected concentration is also the limit of the test system response .
Beth Jacques, B.Sc., and Gerald McDonnell, Ph.D., Biotest
Laboratories * Contributing Writers
The assay was validated in 2012 to support the use of TGA as a release assay for Biotest
Pharmaceuticals Corporation's U.S.
Germany's Merck KG said last month it was no longer delivering its cancer drug Erbitux to Greek hospitals , and Biotest
, which makes products from blood plasma to treat haemophilia and tetanus, stopped shipments in June because of unpaid bills.
(SeeNews) - Nov 13, 2012 - German biotechnology firm Biotest
AG (ETR:BIO3) today reported a net profit of EUR 15.6 million (USD 19.8m) for the first nine months of 2012, which corresponds to an improvement of 6.8% in annual terms